A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia

BACKGROUND: B‐precursor cell acute lymphoblastic leukemia (B‐ALL) in adults is an aggressive and challenging condition, and patients with relapsed/refractory (R/R) disease after allogeneic stem cell transplantation (SCT), or noncandidates for SCT, have a particularly poor prognosis. The authors inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Klisovic, Rebecca B., Leung, Wing H., Brugger, Wolfram, Dirnberger‐Hertweck, Maren, Winderlich, Mark, Ambarkhane, Sumeet V., Jabbour, Elias J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292493/
https://www.ncbi.nlm.nih.gov/pubmed/34343354
http://dx.doi.org/10.1002/cncr.33796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292493/
https://www.ncbi.nlm.nih.gov/pubmed/34343354
http://dx.doi.org/10.1002/cncr.33796

Ejemplares similares